C-reactive protein: Risk factor, biomarker and/or therapeutic target?

Canadian Journal of Cardiology

Volumn 26, Issue SUPPLA, 2010, Pages 41A-44A

  Genest, Jacques ^a  

^a ROYAL VICTORIA HOSPITAL   (Canada)

Author keywords

C reactive protein; Cardiovascular risk; Guidelines; Prevention; Statins

Indexed keywords

BIOLOGICAL MARKER; C REACTIVE PROTEIN; HIGH SENSITIVITY C REACTIVE PROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 6; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NITRIC OXIDE; PHOSPHOLIPID; RNA; ROSUVASTATIN; UNCLASSIFIED DRUG;

ACUTE CORONARY SYNDROME; AGE DISTRIBUTION; APOPTOSIS; ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; DYSLIPIDEMIA; GENE LOCUS; GENETIC VARIABILITY; GENOTYPE; HUMAN; INFLAMMATION; NONHUMAN; PRIMARY PREVENTION; SIGNAL TRANSDUCTION; VASCULAR ENDOTHELIUM; ANIMAL; BLOOD; REVIEW; RISK ASSESSMENT; RISK FACTOR;

ANIMALS; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CARDIOVASCULAR DISEASES; HUMANS; RISK ASSESSMENT; RISK FACTORS;

EID: 77952776228     PISSN: 0828282X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0828-282X(10)71061-8     Document Type: Article

References (30)

1. Pepys MB, Hirschfield GM. C-reactive protein: A critical update. J Clin Invest 2003;111:1805-12.
2. Graf J, Scherzer R, Grunfeld C, Imboden J. Levels of C-reactive protein associated with high and very high cardiovascular risk are prevalent in patients with rheumatoid arthritis. PLoS One 2009;4:e6242.
3. Genest J. Preventive cardiology: Move over LDL-C, hello CRP? Can J Cardiol 2004;(Suppl B):89B-92B.
4. Ridker PM, Danielson E, Fonseca FA, et al; JUPITER Study Group. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008;359:2195-207.
5. Ridker PM, Rifai N, Cook NR, Bradwin G, Buring JE. Non-HDL cholesterol, apolipoproteins A-I and B-100, standard lipid measures, lipid ratios, and CRP as risk factors for cardiovascular disease in women. JAMA 2005;294:326-33.
6. Arima H, Kubo M, Yonemoto K, et al. High-sensitivity C-reactive protein and coronary heart disease in a general population of Japanese: The Hisayama study. Arterioscler Thromb Vasc Biol 2008;28:1385-91.
7. Danesh J. C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. New Engl J Med 2004;350:1387-97.
8. Melander O, Newton-Cheh C, Almgren P, et al. Novel and conventional biomarkers for prediction of incident cardiovascular events in the community. JAMA 2009;302:49-57.
9. NACB LMPG Committee Members, Myers GL, Christenson RH, Cushman M, et al. National Academy of Clinical Biochemistry Laboratory Medicine Practice guidelines: Emerging biomarkers for primary prevention of cardiovascular disease. Clin Chem 2009;55:378-84.
10. Ridker PM, Buring JE, Cook NR, Rifai N. C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events. Circulation 2003;107:391-7.
11. Alberti KG, Zimmet P, Shaw J. The metabolic syndrome - a new worldwide definition. Lancet 2005;366:1059-62.
12. Galassi A, Reynolds K, He J. Metabolic syndrome and risk of cardiovascular disease: A meta-analysis. Am J Med 2006;119:812-9.
13. Verma S, Szmitko PE, Ridker PM. C-reactive protein comes of age. Nat Clin Pract Cardiovasc Med 2004;2:29-36.
14. Pepys MB, Hawkins PN, Kahan MC, et al. Proinflammatory effects of bacterial recombinant human C-reactive protein are caused by contamination with bacterial products, not by C-reactive protein itself. Circ Res 2005;97:e97-103.
15. Zacho J, Tybjaerg-Hansen A, Jensen JS, Grande P, Sillesen H, Nordestgaard BG. Genetically elevated C-reactive protein and ischemic vascular disease. N Engl J Med 2008;359:1897-908.
16. Torzewski M, Reifenberg K, Cheng F, et al. No effect of C-reactive protein on early atherosclerosis in LDLR-/-/human C-reactive protein transgenic mice. Thromb Haemost 2008;99:196-201.
17. Tennent GA, Hutchinson WL, Kahan MC, et al. Transgenic human CRP is not pro-atherogenic, pro-atherothrombotic or proinflammatory in apoE-/- mice. Atherosclerosis 2008;196:248-55.
18. Hirschfield GM, Gallimore JR, Kahan MC, et al. Transgenic human C-reactive protein is not proatherogenic in apolipoprotein E-deficient mice. Proc Natl Acad Sci U S A 2005;102:8309-14.
19. Ortiz MA, Campana GL, Woods JR, et al. Continuously-infused human C-reactive protein is neither proatherosclerotic nor proinflammatory in apolipoprotein E-deficient mice. Exp Biol Med 2009;234:624-31.
20. Trion A, de Maat MP, Jukema JW, et al. No effect of C-reactive protein on early atherosclerosis development in apolipoprotein E*3- Leiden/human C-reactive protein transgenic mice. Arterioscler Thromb Vasc Biol 2005;25:1635-40.
21. Pepys MB, Hirschfield GM, Tennent GA, et al. Targeting C-reactive protein for the treatment of cardiovascular disease. Nature 2006;440:1217-21.
22. Murphy SA, Cannon CP, Wiviott SD, et al. Effect of intensive lipid-lowering therapy on mortality after acute coronary syndrome (a patient-level analysis of the Aggrastat to Zocor and Pravastatin or Atorvastatin Evaluation and Infection Therapy - Thrombolysis in Myocardial Infarction 22 trials). Am J Cardiol 2007;100:1047-51.
23. Ridker PM, Danielson E, Fonseca FA, et al; on behalf of the JUPITER Trial Study Group. Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: A prospective study of the JUPITER trial. Lancet 2009;373:1175-82.
24. Genest J, McPherson R, Frohlich J, et al. 2009 Canadian Cardiovascular Society/Canadian guidelines for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease in the adult - 2009 recommendations. Can J Cardiol 2009;25:567-79.
25. D'Agostino RB, Ramachandran SV, Pencina MJ, et al. General cardiovascular risk profile for use in primary care. The Framingham Heart Study. Circulation 2008;117:743-53.
26. Libby P, Ridker PM. Inflammation and atherosclerosis: Role of C-reactive protein in risk assessment. Am J Med 2004;116(Suppl 6A):9S-16S.
27. Ridker PM, Buring JE, Rifai N, Cook NR. Development and validation of improved algorithms for the assessment of global cardiovascular risk in women: The Reynolds Risk Score. JAMA 2007;297:611-9.
28. Ridker PM, Paynter NP, Rifai N, Gaziano JM, Cook NR. C-reactive protein and parental history improve global cardiovascular risk prediction: The Reynolds Risk Score for men. Circulation 2008;118:2243-51.
29. Fruchart JC, Sacks F, Hermans MP, et al. The Residual Risk Reduction Initiative: A call to action to reduce residual vascular risk in patients with dyslipidemia. Am J Cardiol 2008;102(10 Suppl):1K-34K.
30. Baigent C, Keech A, Kearney PM, et al. Efficacy and safety of cholesterol-lowering treatment: Prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005;366:1267-78.